A cell-based drug discovery assay identifies inhibition of cell stress responses as a new approach to treatment of epidermolysis bullosa simplex

Page view(s)
25
Checked on Apr 14, 2025
A cell-based drug discovery assay identifies inhibition of cell stress responses as a new approach to treatment of epidermolysis bullosa simplex
Title:
A cell-based drug discovery assay identifies inhibition of cell stress responses as a new approach to treatment of epidermolysis bullosa simplex
Journal Title:
Journal of Cell Science
Publication Date:
01 October 2021
Citation:
Tan, T. S., Common, J. E. A., Lim, J. S. Y., Badowski, C., Firdaus, M. J., Leonardi, S. S., & Lane, E. B. (2021). A cell-based drug discovery assay identifies inhibition of cell stress responses as a new approach to treatment of epidermolysis bullosa simplex. Journal of Cell Science, 134(19). https://doi.org/10.1242/jcs.258409
Abstract:
ABSTRACT In the skin fragility disorder epidermolysis bullosa simplex (EBS), mutations in keratin 14 (K14, also known as KRT14) or keratin 5 (K5, also known as KRT5) lead to keratinocyte rupture and skin blistering. Severe forms of EBS are associated with cytoplasmic protein aggregates, with elevated kinase activation of ERK1 and ERK2 (ERK1/2; also known as MAPK3 and MAPK1, respectively), suggesting intrinsic stress caused by misfolded keratin protein. Human keratinocyte EBS reporter cells stably expressing GFP-tagged EBS-mimetic mutant K14 were used to optimize a semi-automated system to quantify the effects of test compounds on keratin aggregates. Screening of a protein kinase inhibitor library identified several candidates that reduced aggregates and impacted on epidermal growth factor receptor (EGFR) signalling. EGF ligand exposure induced keratin aggregates in EBS reporter keratinocytes, which was reversible by EGFR inhibition. EBS keratinocytes treated with a known EGFR inhibitor, afatinib, were driven out of activation and towards quiescence with minimal cell death. Aggregate reduction was accompanied by denser keratin filament networks with enhanced intercellular cohesion and resilience, which when extrapolated to a whole tissue context would predict reduced epidermal fragility in EBS patients. This assay system provides a powerful tool for discovery and development of new pathway intervention therapeutic avenues for EBS.
License type:
Attribution 4.0 International (CC BY 4.0)
Funding Info:
This research / project is supported by the DEBRA - International grants LANE2/LANE3 to E.B.L.
Grant Reference no. : NA

This research / project is supported by the Biomedical Research Council of Singapore - NA
Grant Reference no. : IAF311011

This research / project is supported by the Biomedical Research Council of Singapore - NA
Grant Reference no. : SPF2013/004
Description:
ISSN:
0021-9533
1477-9137
Collections:
Files uploaded:

File Size Format Action
jcs258409.pdf 22.60 MB PDF Open